GlassScriptPhysician profile
Richard A Cottiero
NPI 1295733988
$219,936.94
in general payments reported to CMS, 2019-2025
34 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $14K · 2021: $53K · 2022: $52K · 2023: $22K · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $13K · Food and Beverage: $7,751 · Travel and Lodging: $6,931 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,800 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,875.00 |
| Consulting Fee | $13,400.00 |
| Food and Beverage | $7,750.88 |
| Travel and Lodging | $6,930.58 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,800.00 |
| Education | $234.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49,605.51 | 2019-2025 | Farxiga, Lokelma, Dutoprol |
| Travere Therapeutics, INC. | $49,369.74 | 2019-2025 | Filspari |
| Akebia Therapeutics INC | $35,084.94 | 2019-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $33,174.63 | 2021-2025 | |
| Vifor Pharma, INC. | $19,103.49 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $13,984.95 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $9,785.68 | 2019-2024 | Ultomiris |
| Amgen INC. | $4,086.94 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Janssen Pharmaceuticals, INC | $917.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $593.43 | 2023-2025 | |
| Horizon Therapeutics Plc | $562.10 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.65 | 2019-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $443.06 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $386.45 | 2021-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $338.46 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $320.75 | 2019-2023 | Rayaldee |
| Calliditas Therapeutics US INC. | $289.96 | 2022-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $222.59 | 2020-2024 | Terlivaz |
| Daiichi Sankyo INC. | $215.97 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $156.34 | 2024-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $130.51 | 2021-2023 | Rybelsus, Ozempic |
| Arbor Pharmaceuticals, INC. | $128.26 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Empaveli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.92 | 2021 | |
| Pfizer INC. | $65.62 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.57 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $40.79 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.45 | 2020-2021 | |
| Lilly USA, LLC | $37.78 | 2024-2025 | Jardiance |
| Strongbridge US INC. | $37.59 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $23.22 | 2019 | |
| Kyowa Kirin, INC. | $22.97 | 2025 | |
| Mallinckrodt Enterprises LLC | $21.76 | 2019 | |
| Shire North American Group INC | $17.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cottiero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.